{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:54:09Z","timestamp":1789700049686,"version":"4.0.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010946","name":"UC | UC San Francisco | School of Medicine, University of California, San Francisco","doi-asserted-by":"publisher","award":["Program for Breakthrough Biomedical Research"],"award-info":[{"award-number":["Program for Breakthrough Biomedical Research"]}],"id":[{"id":"10.13039\/100010946","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010946","name":"UC | UC San Francisco | School of Medicine, University of California, San Francisco","doi-asserted-by":"publisher","award":["RRP IMIA"],"award-info":[{"award-number":["RRP IMIA"]}],"id":[{"id":"10.13039\/100010946","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["1S10OD028511-01"],"award-info":[{"award-number":["1S10OD028511-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["F30CA239476"],"award-info":[{"award-number":["F30CA239476"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["5R01CA244550"],"award-info":[{"award-number":["5R01CA244550"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["GRFP"],"award-info":[{"award-number":["GRFP"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["GRFP"],"award-info":[{"award-number":["GRFP"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001384","name":"Samuel Waxman Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001384","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The clinical success of cancer drug candidates depends on efficacy across many different individuals. Because xenografts are challenging to scale, we currently rely on a limited set of in vivo preclinical models. Here, to address this limitation, we introduce GENEVA, a scalable single-cell-resolution platform for measuring responses to drug perturbations. GENEVA models cancer genetic diversity by combining multiple patient-derived cell lines and cancer cell lines into pooled three-dimensional cultures and xenograft models, allowing us to study drug responses across a wide range of genetic backgrounds within a single experiment. We apply GENEVA to investigate KRAS-G12C inhibitors and demonstrate that mitochondrial activation is a key driver of cell death following KRAS inhibition, while epithelial-to-mesenchymal transition is a prominent resistance mechanism. These findings highlight the utility of GENEVA to identify therapeutic targets and optimize combination therapies with the potential to bridge the gap between preclinical cancer models and patient outcomes.<\/jats:p>","DOI":"10.1038\/s43018-026-01130-5","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:04:21Z","timestamp":1771927461000},"page":"522-537","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The GENEVA platform models tumor mosaicism to reveal variations of responses to KRAS inhibitors and identify improved drug combinations"],"prefix":"10.1038","volume":"7","author":[{"given":"Johnny X.","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1210-8460","authenticated-orcid":false,"given":"Jung Min","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina D.","family":"Popova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9868-8397","authenticated-orcid":false,"given":"Kristle","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5051-7927","authenticated-orcid":false,"given":"Tanvi","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Culbertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3657-4578","authenticated-orcid":false,"given":"Jessica B.","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishvak","family":"Subramanyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4939-4381","authenticated-orcid":false,"given":"Kevin","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trey","family":"Charbonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8590-7741","authenticated-orcid":false,"given":"Kevan M.","family":"Shokat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2445-670X","authenticated-orcid":false,"given":"Jonathan","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9648-8949","authenticated-orcid":false,"given":"Hani","family":"Goodarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"1130_CR1","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714\u2013726 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"1130_CR2","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883\u2013892 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1130_CR3","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/2159-8290.CD-22-0158","volume":"12","author":"A Weiss","year":"2022","unstructured":"Weiss, A. et al. Discovery, preclinical characterization, and early clinical activity of JDQ443, a structurally novel, potent, and selective covalent oral inhibitor of KRASG12C. Cancer Discov. 12, 1500\u20131517 (2022).","journal-title":"Cancer Discov."},{"key":"1130_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189\u2013196 (2016).","journal-title":"Science"},{"key":"1130_CR5","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1016\/j.cell.2021.11.017","volume":"184","author":"S Raghavan","year":"2021","unstructured":"Raghavan, S. et al. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell 184, 6119\u20136137 (2021).","journal-title":"Cell"},{"key":"1130_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13059-020-1926-6","volume":"21","author":"D L\u00e4hnemann","year":"2020","unstructured":"L\u00e4hnemann, D. et al. Eleven grand challenges in single-cell data science. Genome Biol. 21, 31 (2020).","journal-title":"Genome Biol."},{"key":"1130_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon, J. et al. The clinical KRASG12C inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217\u2013223 (2019).","journal-title":"Nature"},{"key":"1130_CR8","doi-asserted-by":"publisher","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","volume":"63","author":"JB Fell","year":"2020","unstructured":"Fell, J. B. et al. Identification of the clinical development candidate, a covalent KRAS inhibitor for the treatment of cancer. J. Med. Chem. 63, 6679\u20136693 (2020).","journal-title":"J. Med. Chem."},{"key":"1130_CR9","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1200\/JCO.22.02524","volume":"41","author":"GK Dy","year":"2023","unstructured":"Dy, G. K. et al. Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-year analysis of CodeBreaK 100. J. Clin. Oncol. 41, 3311\u20133317 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1130_CR10","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41417-021-00383-9","volume":"29","author":"J Liu","year":"2021","unstructured":"Liu, J., Kang, R. & Tang, D. The RAS-G12C inhibitor: activity and resistance. Cancer Gene Ther. 29, 875\u2013878 (2021).","journal-title":"Cancer Gene Ther."},{"key":"1130_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fcell.2016.00033","volume":"4","author":"C Wellbrock","year":"2016","unstructured":"Wellbrock, C. & Arozarena, I. The complexity of the ERK\/MAP-kinase pathway and the treatment of melanoma skin cancer. Front. Cell Dev. Biol. 4, 33 (2016).","journal-title":"Front. Cell Dev. Biol."},{"key":"1130_CR12","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1126\/science.aam7622","volume":"355","author":"B Papke","year":"2017","unstructured":"Papke, B. & Der, C. J. Drugging RAS: know the enemy. Science 355, 1158\u20131163 (2017).","journal-title":"Science"},{"key":"1130_CR13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-RasG12C inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548\u2013551 (2013).","journal-title":"Nature"},{"key":"1130_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1755-148X.2010.00685.x","volume":"23","author":"R Halaban","year":"2010","unstructured":"Halaban, R. et al. PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res. 23, 190\u2013200 (2010).","journal-title":"Pigment Cell Melanoma Res."},{"key":"1130_CR15","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41592-019-0433-8","volume":"16","author":"CS McGinnis","year":"2019","unstructured":"McGinnis, C. S. et al. MULTI-seq: sample multiplexing for single-cell RNA sequencing using lipid-tagged indices. Nat. Methods 16, 619\u2013626 (2019).","journal-title":"Nat. Methods"},{"key":"1130_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nbt.4042","volume":"36","author":"HM Kang","year":"2017","unstructured":"Kang, H. M. et al. Multiplexed droplet single-cell RNA-sequencing using natural genetic variation. Nat. Biotechnol. 36, 89\u201394 (2017).","journal-title":"Nat. Biotechnol."},{"key":"1130_CR17","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1158\/1535-7163.MCT-16-0025","volume":"15","author":"J Peh","year":"2016","unstructured":"Peh, J., Fan, T. M., Wycislo, K. L., Roth, H. S. & Hergenrother, P. J. The combination of vemurafenib and procaspase-3 activation is synergistic in mutant BRAF melanomas. Mol. Cancer Ther. 15, 1859\u20131869 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"1130_CR18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-15-1105","volume":"6","author":"MP Patricelli","year":"2016","unstructured":"Patricelli, M. P. et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 6, 316\u2013329 (2016).","journal-title":"Cancer Discov."},{"key":"1130_CR19","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1016\/j.celrep.2020.03.021","volume":"30","author":"N Santana-Codina","year":"2020","unstructured":"Santana-Codina, N. et al. Defining and targeting adaptations to oncogenic KRASG12C inhibition using quantitative temporal proteomics. Cell Rep. 30, 4584\u20134599 (2020).","journal-title":"Cell Rep."},{"key":"1130_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-019-0829-z","volume":"13","author":"GJ Yoshida","year":"2020","unstructured":"Yoshida, G. J. Applications of patient-derived tumor xenograft models and tumor organoids. J. Hematol. Oncol. 13, 4 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"1130_CR21","doi-asserted-by":"publisher","first-page":"eaaw9450","DOI":"10.1126\/scisignal.aaw9450","volume":"12","author":"K Lou","year":"2019","unstructured":"Lou, K. et al. KRASG12C inhibition produces a driver-limited state revealing collateral dependencies. Sci. Signal. 12, eaaw9450 (2019).","journal-title":"Sci. Signal."},{"key":"1130_CR22","doi-asserted-by":"publisher","first-page":"D1541","DOI":"10.1093\/nar\/gkaa1011","volume":"49","author":"S Rath","year":"2021","unstructured":"Rath, S. et al. MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotations. Nucleic Acids Res. 49, D1541\u2013D1547 (2021).","journal-title":"Nucleic Acids Res."},{"key":"1130_CR23","doi-asserted-by":"publisher","first-page":"10696","DOI":"10.18632\/oncotarget.7372","volume":"7","author":"K Yamaguchi","year":"2016","unstructured":"Yamaguchi, K. et al. A synthetic-lethality RNAi screen reveals an ERK\u2013mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. Oncotarget 7, 10696 (2016).","journal-title":"Oncotarget"},{"key":"1130_CR24","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.1021\/acs.jmedchem.8b00583","volume":"61","author":"H Shao","year":"2018","unstructured":"Shao, H. et al. Exploration of benzothiazole-rhodacyanines as allosteric inhibitors of protein\u2013protein interactions with heat shock protein 70 (HSP70). J. Med. Chem. 61, 6163\u20136177 (2018).","journal-title":"J. Med. Chem."},{"key":"1130_CR25","doi-asserted-by":"publisher","first-page":"e1008057","DOI":"10.1371\/journal.pgen.1008057","volume":"15","author":"N Liaud","year":"2019","unstructured":"Liaud, N. et al. Cellular response to small molecules that selectively stall protein synthesis by the ribosome. PLoS Genet. 15, e1008057 (2019).","journal-title":"PLoS Genet."},{"key":"1130_CR26","doi-asserted-by":"publisher","first-page":"e2004624","DOI":"10.1371\/journal.pbio.2004624","volume":"16","author":"BA Mendelsohn","year":"2018","unstructured":"Mendelsohn, B. A. et al. A high-throughput screen of real-time ATP levels in individual cells reveals mechanisms of energy failure. PLoS Biol. 16, e2004624 (2018).","journal-title":"PLoS Biol."},{"key":"1130_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/978-1-0716-2309-1_12","volume":"2497","author":"J Pfleger","year":"2022","unstructured":"Pfleger, J. Measurements of mitochondrial respiration in intact cells, permeabilized cells, and isolated tissue mitochondria using the Seahorse XF analyzer. Methods Mol. Biol. 2497, 185\u2013206 (2022).","journal-title":"Methods Mol. Biol."},{"key":"1130_CR28","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/biology12040597","volume":"12","author":"M Strickland","year":"2023","unstructured":"Strickland, M. et al. Mitochondrial Dysfunction in CD4+ T effector memory RA+ cells. Biology 12, 597 (2023).","journal-title":"Biology"},{"key":"1130_CR29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/S0014-5793(99)00696-1","volume":"453","author":"EH Pap","year":"1999","unstructured":"Pap, E. H. et al. Ratio-fluorescence microscopy of lipid oxidation in living cells using C11-BODIPY581\/591. FEBS Lett. 453, 278\u2013282 (1999).","journal-title":"FEBS Lett."},{"key":"1130_CR30","doi-asserted-by":"publisher","first-page":"bio043182","DOI":"10.1242\/bio.043182","volume":"8","author":"HM Tang","year":"2019","unstructured":"Tang, H. M. & Tang, H. L. Cell recovery by reversal of ferroptosis. Biol. Open 8, bio043182 (2019).","journal-title":"Biol. Open"},{"key":"1130_CR31","doi-asserted-by":"publisher","first-page":"eaaw7999","DOI":"10.1126\/scitranslmed.aaw7999","volume":"11","author":"M Molina-Arcas","year":"2019","unstructured":"Molina-Arcas, M. et al. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. Sci. Transl. Med. 11, eaaw7999 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1130_CR32","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","volume":"577","author":"JY Xue","year":"2020","unstructured":"Xue, J. Y. et al. Rapid non-uniform adaptation to conformation-specific KRASG12C inhibition. Nature 577, 421\u2013425 (2020).","journal-title":"Nature"},{"key":"1130_CR33","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/19466315.2018.1437071","volume":"10","author":"Q Liu","year":"2018","unstructured":"Liu, Q., Yin, X., Languino, L. R. & Altieri, D. C. Evaluation of drug combination effect using a Bliss independence dose\u2013response surface model. Stat. Biopharm. Res. 10, 112\u2013122 (2018).","journal-title":"Stat. Biopharm. Res."},{"key":"1130_CR34","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3389\/fonc.2020.00486","volume":"10","author":"SY Tam","year":"2020","unstructured":"Tam, S. Y., Wu, V. W. C. & Law, H. K. W. Hypoxia-induced epithelial\u2013mesenchymal transition in cancers: HIF-1\u03b1 and beyond. Front. Oncol. 10, 486 (2020).","journal-title":"Front. Oncol."},{"key":"1130_CR35","first-page":"4479","volume":"9","author":"S Herbertz","year":"2015","unstructured":"Herbertz, S. et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-\u03b2 signaling pathway. Drug Des. Devel. Ther. 9, 4479\u20134499 (2015).","journal-title":"Drug Des. Devel. Ther."},{"key":"1130_CR36","doi-asserted-by":"publisher","first-page":"e81856","DOI":"10.7554\/eLife.81856","volume":"11","author":"JM Replogle","year":"2022","unstructured":"Replogle, J. M. et al. Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors. Elife 11, e81856 (2022).","journal-title":"Elife"},{"key":"1130_CR37","doi-asserted-by":"publisher","first-page":"110993","DOI":"10.1016\/j.celrep.2022.110993","volume":"39","author":"MB Ryan","year":"2022","unstructured":"Ryan, M. B. et al. KRAS-independent feedback activation of wild-type RAS constrains KRAS inhibitor efficacy. Cell Rep. 39, 110993 (2022).","journal-title":"Cell Rep."},{"key":"1130_CR38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin, J. et al. The KRAS inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 10, 54\u201371 (2020).","journal-title":"Cancer Discov."},{"key":"1130_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/bs.acr.2021.07.008","volume":"153","author":"JN Diehl","year":"2022","unstructured":"Diehl, J. N. et al. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. Adv. Cancer Res. 153, 101\u2013130 (2022).","journal-title":"Adv. Cancer Res."},{"key":"1130_CR40","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41698-022-00329-w","volume":"6","author":"T McFall","year":"2022","unstructured":"McFall, T. et al. Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS\u2022GTP. Precision Oncology 6, 86 (2022).","journal-title":"Precision Oncology"},{"key":"1130_CR41","doi-asserted-by":"publisher","first-page":"4296","DOI":"10.1038\/s41467-020-17440-w","volume":"11","author":"JM McFarland","year":"2020","unstructured":"McFarland, J. M. et al. Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action. Nat. Commun. 11, 4296 (2020).","journal-title":"Nat. Commun."},{"key":"1130_CR42","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs, N. et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172, 373\u2013386 (2018).","journal-title":"Cell"},{"key":"1130_CR43","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad, M. M. et al. Acquired resistance to KRAS inhibition in cancer. N. Engl. J. Med. 384, 2382\u20132393 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1130_CR44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1158\/2159-8290.CD-22-0405","volume":"13","author":"R Yaeger","year":"2023","unstructured":"Yaeger, R. et al. Molecular characterization of acquired resistance to KRASG12C\u2013EGFR inhibition in colorectal cancer. Cancer Discov. 13, 41\u201355 (2023).","journal-title":"Cancer Discov."},{"key":"1130_CR45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/genes13020235","volume":"13","author":"C Lee","year":"2022","unstructured":"Lee, C. Towards the genetic architecture of complex gene expression traits: challenges and prospects for eQTL mapping in humans. Genes 13, 235 (2022).","journal-title":"Genes"},{"key":"1130_CR46","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.cell.2016.11.038","volume":"167","author":"A Dixit","year":"2016","unstructured":"Dixit, A. et al. Perturb-Seq: dissecting molecular circuits with scalable single-cell RNA profiling of pooled genetic screens. Cell 167, 1853\u20131866 (2016).","journal-title":"Cell"},{"key":"1130_CR47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1126\/science.aax6234","volume":"367","author":"SR Srivatsan","year":"2020","unstructured":"Srivatsan, S. R. et al. Massively multiplex chemical transcriptomics at single-cell resolution. Science 367, 45\u201351 (2020).","journal-title":"Science"},{"key":"1130_CR48","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.cell.2020.09.044","volume":"183","author":"D Kim","year":"2020","unstructured":"Kim, D., Xue, J. Y. & Lito, P. Targeting KRASG12C: from inhibitory mechanism to modulation of antitumor effects in patients. Cell 183, 850\u2013859 (2020).","journal-title":"Cell"},{"key":"1130_CR49","doi-asserted-by":"publisher","unstructured":"Leko, I. M.et al. Generation and expansion of transitional lung organoids from human pluripotent stem cells. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.01.30.526265 (2023).","DOI":"10.1101\/2023.01.30.526265"},{"key":"1130_CR50","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/cyto.a.23898","volume":"97","author":"D Ordo\u00f1ez-Rueda","year":"2020","unstructured":"Ordo\u00f1ez-Rueda, D. et al. Apoptotic cell exclusion and bias-free single-cell selection are important quality control requirements for successful single-cell sequencing applications. Cytometry A 97, 156\u2013167 (2020).","journal-title":"Cytometry A"},{"key":"1130_CR51","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.molcel.2009.11.016","volume":"36","author":"H Goodarzi","year":"2009","unstructured":"Goodarzi, H., Elemento, O. & Tavazoie, S. Revealing global regulatory perturbations across human cancers. Mol. Cell 36, 900\u2013911 (2009).","journal-title":"Mol. Cell"},{"key":"1130_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"1130_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07992-4","volume":"16","author":"C Zhou","year":"2025","unstructured":"Zhou, C. et al. WEE1 inhibitor exerts synergistic effect with KRAS G12C inhibitor via MYBL2\u2013RRM2 axis in KRASG12C-mutant lung cancer. Cell Death Dis. 16, 661 (2025).","journal-title":"Cell Death Dis."},{"key":"1130_CR54","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.molcel.2017.09.012","volume":"68","author":"M Jost","year":"2017","unstructured":"Jost, M. et al. Combined CRISPRi\/a-based chemical genetic screens reveal that rigosertib is a microtubule-destabilizing agent. Mol. Cell 68, 210\u2013223 (2017).","journal-title":"Mol. Cell"},{"key":"1130_CR55","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.abl5829","volume":"378","author":"K Lou","year":"2022","unstructured":"Lou, K. et al. IFITM proteins assist cellular uptake of diverse linked chemotypes. Science 378, 1097\u20131104 (2022).","journal-title":"Science"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01130-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01130-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01130-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T10:02:09Z","timestamp":1774864929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01130-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":55,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["1130"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01130-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.12.13.628239","asserted-by":"object"}]},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"16 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.X.Y., K.M.S. and H.G. are cofounders and shareholders of Tahoe Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}